vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Ecovyst Inc. (ECVT). Click either name above to swap in a different company.

ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $199.4M, roughly 1.3× Ecovyst Inc.). On growth, Ecovyst Inc. posted the faster year-over-year revenue change (34.0% vs 9.7%). Over the past eight quarters, Ecovyst Inc.'s revenue compounded faster (18.7% CAGR vs 5.3%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

ACAD vs ECVT — Head-to-Head

Bigger by revenue
ACAD
ACAD
1.3× larger
ACAD
$268.1M
$199.4M
ECVT
Growing faster (revenue YoY)
ECVT
ECVT
+24.2% gap
ECVT
34.0%
9.7%
ACAD
Faster 2-yr revenue CAGR
ECVT
ECVT
Annualised
ECVT
18.7%
5.3%
ACAD

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ACAD
ACAD
ECVT
ECVT
Revenue
$268.1M
$199.4M
Net Profit
$3.6M
Gross Margin
23.4%
Operating Margin
-1.7%
10.9%
Net Margin
1.4%
Revenue YoY
9.7%
34.0%
Net Profit YoY
EPS (diluted)
$0.02
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
ECVT
ECVT
Q1 26
$268.1M
Q4 25
$284.0M
$199.4M
Q3 25
$278.6M
$204.9M
Q2 25
$264.6M
$176.1M
Q1 25
$244.3M
$143.1M
Q4 24
$259.6M
$148.9M
Q3 24
$250.4M
$153.9M
Q2 24
$242.0M
$154.0M
Net Profit
ACAD
ACAD
ECVT
ECVT
Q1 26
$3.6M
Q4 25
$273.6M
Q3 25
$71.8M
$-79.3M
Q2 25
$26.7M
$6.0M
Q1 25
$19.0M
$-3.6M
Q4 24
$143.7M
Q3 24
$32.8M
$14.3M
Q2 24
$33.4M
$8.3M
Gross Margin
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
90.8%
23.4%
Q3 25
92.2%
25.4%
Q2 25
92.2%
22.8%
Q1 25
91.7%
13.3%
Q4 24
91.6%
28.9%
Q3 24
92.5%
29.3%
Q2 24
92.5%
27.3%
Operating Margin
ACAD
ACAD
ECVT
ECVT
Q1 26
-1.7%
Q4 25
6.1%
10.9%
Q3 25
12.8%
13.8%
Q2 25
12.2%
9.0%
Q1 25
7.9%
-0.7%
Q4 24
59.1%
15.1%
Q3 24
12.6%
17.9%
Q2 24
12.6%
14.1%
Net Margin
ACAD
ACAD
ECVT
ECVT
Q1 26
1.4%
Q4 25
96.3%
Q3 25
25.8%
-38.7%
Q2 25
10.1%
3.4%
Q1 25
7.8%
-2.5%
Q4 24
55.4%
Q3 24
13.1%
9.3%
Q2 24
13.8%
5.4%
EPS (diluted)
ACAD
ACAD
ECVT
ECVT
Q1 26
$0.02
Q4 25
$1.61
$0.06
Q3 25
$0.42
$-0.69
Q2 25
$0.16
$0.05
Q1 25
$0.11
$-0.03
Q4 24
$0.86
$-0.26
Q3 24
$0.20
$0.12
Q2 24
$0.20
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
ECVT
ECVT
Cash + ST InvestmentsLiquidity on hand
$197.2M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$603.4M
Total Assets
$1.6B
$1.3B
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
$177.7M
$197.2M
Q3 25
$258.0M
$82.0M
Q2 25
$253.6M
$69.6M
Q1 25
$217.7M
$127.5M
Q4 24
$319.6M
$131.4M
Q3 24
$155.1M
$123.5M
Q2 24
$177.1M
$83.3M
Total Debt
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
$392.6M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
Q3 24
$862.7M
Q2 24
$862.4M
Stockholders' Equity
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
$1.2B
$603.4M
Q3 25
$917.3M
$607.9M
Q2 25
$822.4M
$692.4M
Q1 25
$765.2M
$698.7M
Q4 24
$732.8M
$700.5M
Q3 24
$577.2M
$729.4M
Q2 24
$516.7M
$717.3M
Total Assets
ACAD
ACAD
ECVT
ECVT
Q1 26
$1.6B
Q4 25
$1.6B
$1.3B
Q3 25
$1.3B
$1.7B
Q2 25
$1.2B
$1.8B
Q1 25
$1.1B
$1.8B
Q4 24
$1.2B
$1.8B
Q3 24
$976.9M
$1.8B
Q2 24
$914.1M
$1.8B
Debt / Equity
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
0.65×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
Q3 24
1.18×
Q2 24
1.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
ECVT
ECVT
Operating Cash FlowLast quarter
$41.8M
Free Cash FlowOCF − Capex
$22.9M
FCF MarginFCF / Revenue
11.5%
Capex IntensityCapex / Revenue
9.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
$-48.7M
$41.8M
Q3 25
$74.3M
$55.3M
Q2 25
$64.0M
$33.0M
Q1 25
$20.3M
$10.3M
Q4 24
$40.4M
$43.5M
Q3 24
$63.2M
$59.9M
Q2 24
$25.0M
$10.0M
Free Cash Flow
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
$22.9M
Q3 25
$73.9M
$53.2M
Q2 25
$7.8M
Q1 25
$-14.0M
Q4 24
$30.9M
Q3 24
$63.2M
$53.6M
Q2 24
$-9.3M
FCF Margin
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
11.5%
Q3 25
26.5%
26.0%
Q2 25
4.4%
Q1 25
-9.8%
Q4 24
20.7%
Q3 24
25.2%
34.9%
Q2 24
-6.1%
Capex Intensity
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
9.4%
Q3 25
0.1%
1.0%
Q2 25
14.4%
Q1 25
16.9%
Q4 24
8.5%
Q3 24
0.0%
4.1%
Q2 24
12.5%
Cash Conversion
ACAD
ACAD
ECVT
ECVT
Q1 26
Q4 25
-0.18×
Q3 25
1.03×
Q2 25
2.40×
5.52×
Q1 25
1.07×
Q4 24
0.28×
Q3 24
1.93×
4.21×
Q2 24
0.75×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Segment breakdown not available.

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

Related Comparisons